

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to Rule 14a-12

Kadant Inc.

(Name of the Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



Kadant Inc.
One Technology Park Drive
Westford, MA 01886

Commencing May 14, 2012, the following information is being used by Kadant Inc. (the “Company”) to communicate about the Company’s upcoming Annual Meeting of Stockholders and may be sent to certain stockholders.

In its proxy statement dated April 9, 2012, the Company disclosed that one of its directors, Francis L. McKone, had attended less than 75% of the meetings of its board of directors and the committees on which he served during 2011 due to other commitments. In particular, Mr. McKone missed meetings in late spring and summer to undergo treatment for a medical condition, and as a result only attended 70% of the applicable meetings in 2011. The Company believes Mr. McKone’s absences in 2011 were unavoidable and limited to a specific period of time. Since completion of his treatment, his attendance at meetings of the board of directors and committees has been perfect. Under the 2012 US Proxy Voting Summary Guidelines issued January 31, 2012 by ISS Proxy Advisory Services, missing meetings for medical reasons is viewed as a valid excuse.

For these reasons, the Company requests that stockholders cast their votes FOR Mr. McKone’s election and not to withhold their votes.